Gan & Lee Pharmaceuticals reported positive Phase III data for two metabolic programs—its once-weekly basal insulin candidate Ludefen and obesity therapy bofanglutide—signaling renewed momentum for the Chinese diabetes and obesity developer. The update strengthens the company’s position in metabolic disease at a time when competitive pressure remains intense. Phase III success for a long-acting insulin could broaden treatment options in diabetes, while additional efficacy or tolerability signals for bofanglutide could reinforce demand for obesity therapies that aim to balance weight loss with longer-term adherence. Public attention will likely shift to Phase III endpoint detail, safety across the full dosing range, and how quickly the company can transition into regulatory submissions. The report also lands in a period of heightened transaction activity in China-linked biopharma partnerships, with dealmakers searching for clinically validated late-stage assets.